Advertisement

Related Videos

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
29
Today In Oncology
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
F-SHARP Trial Evaluates Focal Salvage Brachytherapy and Genomic Risk Stratification in Recurrent Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo